Twenty-two advanced HLA-A2+ NSCLC patients who had inoperable (stage IIIb or IV) NSCLC with neutrophils ≥1.5 × 109/L and showed immune responses or disease stabilization following 4 rounds of a first-line platinum-based chemotherapy were eligible to receive IFNγ DCexos [81]. This evidence concerns the gene IFNG and non-small cell lung carcinoma.